Intensity Therapeutics Inc. has announced that it received a notice from The Nasdaq Stock Market indicating that its common stock has failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2). This notice does not immediately affect the trading of the company's stock, which will continue to trade under the symbol "INTS" on The Nasdaq Capital Market. The company has until December 3, 2025, to regain compliance by ensuring its stock maintains a closing bid price of at least $1.00 for 10 consecutive business days. Intensity Therapeutics is monitoring the situation and considering options to meet this requirement, but there is no assurance of success. If compliance is not achieved by the deadline, the company may seek additional time to rectify the situation or face potential delisting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.